Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $69.90M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.07M
Average 0.16M
Returns on capital
Coya Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.3%
avg -18.5%
ROIC
-46.0%
avg -78.2%
ROA
-42.5%
avg -59.3%
Analysis
ROA is currently the strongest return metric at -42.5% versus its period average of -59.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Arun Swaminathan | Chief Executive Officer & Director | USD 941.85K | 57 | 293.98K | 1.61% |
Fred Grossman FAPA | President & Chief Medical Officer | USD 787.09K | 67 | — | — |
David S. Snyder | Chief Financial Officer & Chief Operating Officer | USD 698.36K | 66 | 140.04K | 0.77% |
Michelle Frazier | Senior Vice President of Regulatory | — | — | — | — |
Aaron Thome | Head of Neuroinflammation Platform | — | — | — | — |
Karen King | Senior Vice President of Program Management & Clinical Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 22, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -33.9% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -33.9% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Coya Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about COYA's management, answered from reported figures.
Who manages COYA?
Coya Therapeutics, Inc. (COYA) lists 6 active executives. The top listed executive is Fred Grossman FAPA, President & Chief Medical Officer.
Are COYA insiders buying or selling?
Recent insider activity shows net buying of $14.76M.
Continue the stock analysis
Jump to another research area for this company.